Home › Burkitt Lymphoma › New York
Burkitt Lymphoma clinical trials in New York
19 studies for Burkitt Lymphoma are looking for participants at sites in New York.
Cities in New York
- New York City13 studies
- Greenburgh7 studies
- Buffalo7 studies
- The Bronx6 studies
- Queens6 studies
- Syracuse4 studies
- Rochester4 studies
- Albany4 studies
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07936266Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- and 8 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Nov 12, 2026 · NCT07223021Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Roswell Park Cancer Institute, Buffalo
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- and 4 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- and 7 more
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- and 9 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- New York Medical College, Valhalla
RecruitingPhase 2
Ages 3 to 31 · All sexes · Updated Oct 23, 2026 · NCT02393157Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137118Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 to 54 · All sexes · Updated Oct 13, 2026 · NCT06918431Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 12 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
RecruitingPhase 1/2
Ages 12 to 70 · All sexes · Updated Apr 15, 2026 · NCT04491370Study of SGR-1505 in Mature B-Cell Neoplasms
- Roswell Park Comprehensive Cancer Center, Buffalo
- Weill Cornell, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT03595917The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.